Site Management Organization vs CRO: Who Hires Whom

In L.E.K. Consulting's 2022 survey of biopharma and CRO sponsors, 31% of respondents expected to use site management organizations often or regularly for Phase 3 trials in 2023, up from 15% in 2021 [1]. Demand has outrun the vocabulary, since buyers use SMO, CRO and site network as if they named one vendor. A CRO is usually hired by the sponsor to run the trial, while an SMO owns and operates the sites that a sponsor or CRO contracts with, and the rest of the decision follows from that split. Refero does not run recruitment campaigns. We vet and match the clinical research marketing agencies that do, so what follows is written for the buyer, from what those vendors need and see.

Site management organization at a glance

The published figures describe sponsor demand and how sites are paid; none measures an SMO's own results, so the buyer has to ask for them.

• 31% of surveyed sponsors expected to use SMOs often or regularly for Phase 3 trials in 2023, up from 15% in 2021 [1]
• Study sites are paid by the number of patients enrolled, and sites with abnormal screen-failure rates can be excluded from new studies [2]
• Nominal total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, and tracked biomedical R&D prices once the researchers adjusted for fewer patients per site and more work per patient [3]
• A sponsor obligation that the written transfer to a CRO does not describe is considered not transferred [4]

What a Site Management Organization Does

L.E.K. Consulting defines site management organizations as organizations that own multiple commercial clinical trial sites and offer dedicated site management services and a single touchpoint for sponsors [5]. The services it lists are patient recruitment, institutional review board documentation, trial site selection, trial site contracting and data reporting [5].

That list is operational and contractual work, which is what the buyer is paying for, so each item is worth asking the SMO to evidence. Patient recruitment is only one of those services, and the clinical trial patient recruitment benchmarks show how long enrollment takes and why it slips.

L.E.K.'s definition ties an SMO to owning sites, and the value it describes rests on one contract and one point of contact across that network [5]. The buyer should therefore ask what an SMO owns and what it contracts before assuming the label means a network of enrolling clinics.

How to Choose a Site Management Organization

Choose a site management organization on the evidence a sponsor would need to oversee it, because the sponsor stays responsible for the trial whichever organization runs the sites. A sponsor can transfer obligations to a contract research organization only in writing under 21 CFR 312.52, and any obligation the written description does not cover is considered not transferred [4]. ICH E6(R3) says the same from the quality side: tasks may pass to a service provider, but final responsibility for the trial data's quality and integrity stays with the sponsor [6]. Both rules are written for delegated work in general, a CRO under the first and a service provider under the second, so the test they set, whether a delegated task is written down and visible to the sponsor, is the one to apply to an SMO. This is not legal advice; confirm with regulatory counsel and the IRB of record.

Ask for enrollment and screen-failure history in your therapeutic area

Use this whenever an SMO's pitch leads with network size. Ask for enrollment and screen-failure rates by study, in your therapeutic area and at a protocol complexity like yours. Sponsors read the same numbers when they select sites, because sites with historically abnormal screen-failure rates can be excluded from new studies or put under extra scrutiny once they start enrolling [2]. Walk away if the SMO can offer only referral counts or averages across unrelated indications, since neither shows how many patients were randomized and kept.

Confirm which sites and investigators the SMO controls

Use this when the SMO is described as a network. Ask for the list of sites that would run your study, which of them the SMO owns and which it contracts, and the named principal investigator at each, since L.E.K. defines an SMO by its ownership of multiple sites [5]. Walk away if investigators cannot be named before signature, because the network is then a claim rather than a capacity.

Check regulatory standing and quality records before contracting

Use this before any term sheet. The FDA publishes its list of clinical investigators who have been disqualified or are in disqualification proceedings, so a sponsor can check the named investigators against it before signing [7]. Ask the SMO for its inspection history and how it closed the findings. Walk away from an SMO that will not share past inspection outcomes or performance metrics, because ICH E6(R3) expects the sponsor to have access to relevant information, such as SOPs and performance metrics, for selecting and overseeing service providers [6].

Name the coordinators who will run your study

Use this when the SMO, rather than the site's own staff, would supply the coordinators and regulatory staff. Ask for their names, how many concurrent studies each carries and what happens when one leaves. ICH E6(R3) says the investigator should ensure that persons to whom trial-related activities are delegated are adequately informed about the protocol and their assigned activities [6], so staffing continuity is a compliance matter as well as an operational one. Walk away if staff are assigned only after signature.

Put scope, data access and payment triggers in writing

Use this at the term sheet stage. The written scope should list each task the SMO takes on, who holds the data and source records, which events trigger payment and the termination rights, because anything the document leaves undescribed stays with the sponsor [4]. Walk away from a contract that prices enrollment volume without saying what happens to screen failures and withdrawals.

Pick a CRO or a direct site contract when the study is small and regional

Use this when the study runs few sites in one region. L.E.K. finds that sponsors value SMOs most in later-stage trials, where higher patient counts need more sites and data collection grows more complex, and where timelines are tight or coordination spans regions, and it names trials needing fewer sites across a narrower regional footprint as the case where the value is lower [1]. A sponsor with two sites in one metropolitan area has little cross-site coordination to buy, so price the SMO against what the CRO or the sites already provide.

If you would rather not run that evaluation alone, Refero screens healthcare marketing and patient recruitment agencies against five published criteria and introduces up to three that fit your brief. It is free for buyers, and there is no obligation to hire anyone we introduce. Tell us what you need.

Site Management Organization vs CRO and Site Network

The three differ by who contracts with them and what is delegated: a CRO holds work the sponsor transferred in writing, an SMO owns and operates sites and offers sponsors one contract across them, and a site network is a group of sites that may or may not sit under an SMO.

Who hires whom: L.E.K. shows sponsors and CROs as the parties that deal with SMOs and site networks, and the CRO row rests on the written-transfer rule.

The contract carries the real answer, because what each party holds is whatever the document describes. FDA guidance is precise on the CRO side: when a sponsor delegates monitoring, the regulations require that transfer in writing and require the CRO to comply [8].

Site network and SMO get used interchangeably because L.E.K. itself shows them as one box of site operators and defines an SMO as an owner of multiple sites [5]. Network names what an organization owns and SMO names what it does, so one organization can be both and the buyer should ask a bidder which of the two it is offering.

Where a Site Management Organization Fits in Site Selection

An SMO enters while sites are being chosen, either as the organization behind a site or as a vendor the sponsor or CRO engages, and the sponsor's GCP oversight responsibility does not move with it. The sequence starts with the sponsor, which may transfer obligations to a CRO but only under a written description [4]. The sponsor or CRO then selects sites, some of which may sit under an SMO whose listed services include site contracting and IRB documentation [5]. Once a site is active, its work is overseen like any other site's, because ICH E6(R3) leaves final responsibility for data quality and integrity with the sponsor even when tasks pass to service providers [6].

That sequence explains why an SMO changes who does the work at a site without changing who answers for it. A sponsor that buys SMO services through its CRO still needs the SMO's written scope and quality records, since both its own duty and the CRO's delegated duties are defined by documents rather than job titles [4]. This is not legal advice; confirm the allocation of responsibilities with regulatory counsel and the IRB of record.

How Site Management Organizations Are Paid and Whether They Speed Up Enrollment

The published research describes study sites as paid per enrolled patient, and the claim that SMOs speed up enrollment rests on commentary rather than on a published comparison.

The payment mechanism creates the incentive: study sites are paid by the number of patients enrolled rather than by how well those patients meet eligibility criteria, and sites with abnormal screen-failure rates can be excluded from new studies [2]. Under-enrollment therefore costs a site revenue and future selection, which is why a sponsor should ask an SMO what happens to screen failures.

Researchers who built a price index for investigator agreements measured it as total grant cost per patient, which rose in nominal terms by a factor of 4.5 between 1989 and 2011 but tracked biomedical R&D prices once they adjusted for fewer patients per site and more work per patient [3]. A higher per-patient price can therefore reflect more work rather than a higher margin, so quotes are comparable only once the procedures behind them are matched. A buyer can hold a fee quote against sourced per-patient recruitment cost figures.

The speed claim needs the same care, because L.E.K.'s commentary says SMOs "can enable faster trial start-up times and effective patient recruitment and retention" and gives no figure for the speed-up [1]. That makes speed a claim to verify rather than a result to price in. Ask the SMO for its start-up and enrollment metrics, such as time from contract to site activation and enrollment against target at comparable sites, and compare them with your own plan before weighing its fee against the time it promises to save.

Frequently asked questions

What is the difference between a CRO and an SMO?

A CRO is usually hired by the sponsor and takes on trial functions such as monitoring through a written transfer of obligations [4]. An SMO, as L.E.K. defines it, owns multiple trial sites and offers sponsors a single touchpoint for site management services [5]. As a one-line rule, the CRO runs trial functions for the sponsor and the SMO runs the sites it owns.

What is a site management organization?

A site management organization is, in L.E.K. Consulting's definition, an organization that owns multiple commercial clinical trial sites and offers dedicated site management services and a single touchpoint for sponsors [5]. The services it lists are patient recruitment, institutional review board documentation, trial site selection, trial site contracting and data reporting [5].

What is the difference between an SMO and a site network?

Site network names what an organization owns, a group of research sites, while SMO names what it does, which is manage site operations. L.E.K. shows the two as one box of site operators and defines an SMO as an owner of multiple sites [5], which is why the terms get swapped. Ask which of the two a bidder is offering, and what it owns versus contracts.

How are site management organizations paid?

The sources reviewed here do not describe SMO fee schedules. They do show that study sites are paid by the number of patients enrolled rather than by how well those patients meet the eligibility criteria [2], and that grant agreements are priced as a total grant cost per patient [3]. Ask any SMO for the full payment schedule and the triggers behind each fee rather than the per-patient figure alone.

Do site management organizations speed up enrollment?

The published commentary says they can, and gives no figure for the speed-up [1]. L.E.K. finds sponsors value SMOs most in later-stage trials with tight timelines, more sites and higher patient counts, and less where few sites sit in one narrow region [1]. Treat speed as a claim, and ask the SMO for its start-up and enrollment metrics against your protocol's target.

Sources

• Wheeler M. A Shift Toward Trial Site Management Organizations: Trends And Implications For Sponsors. Clinical Leader (L.E.K. Consulting), 2023. Link
• Yang E, O'Donovan C, Phillips J, et al. Quantifying and visualizing site performance in clinical trials. Contemporary Clinical Trials Communications, 2018. Link
• Berndt ER, Cockburn IM. Price Indexes for Clinical Trial Research: A Feasibility Study. National Bureau of Economic Research Working Paper 18918, 2013. Link
• US Food and Drug Administration. 21 CFR 312.52, Transfer of obligations to a contract research organization. Electronic Code of Federal Regulations. Link
• L.E.K. Consulting. Exploring the Risks and Opportunities within Clinical Site Management Organizations. Executive Insights. Link
• International Council for Harmonisation. ICH E6(R3) Guideline for Good Clinical Practice, Step 4, 2025. Link
• US Food and Drug Administration. Clinical Investigators Disqualification Proceedings and Debarment List. Link
• US Food and Drug Administration. Guidance for Industry: Oversight of Clinical Investigations, A Risk-Based Approach to Monitoring, 2013. Link